Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine

British Journal of Pharmacology

Volumn 144, Issue 6, 2005, Pages 821-829

  Kennard, Louise E ^a   Chumbley, Justin R ^a   Ranatunga, Kishani M ^a   Armstrong, Stephanie J ^a   Veale, Emma L ^a   Mathie, Alistair ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

C terminus; Fluoxetine; Norfluoxetine; Potassium current; TASK 3; TREK 1; Two pore domain potassium channel

Indexed keywords

DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE; TANDEM PORE DOMAIN POTASSIUM CHANNEL;

ACIDIFICATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IC 50; PATCH CLAMP; POTASSIUM CHANNEL TASK 3; POTASSIUM CHANNEL TREK 1; PRIORITY JOURNAL; WHOLE CELL;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; SEROTONIN UPTAKE INHIBITORS; TRANSFECTION;

EID: 17144415595     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706068     Document Type: Article

References (46)

1. ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2004). Potassium channels, in Guide to receptors and channels. Br. J. Pharmacol., 141, S83-S84.
2. ALTAMURA, A.C., MORO, A.R. & PERCUDANI, M. (1994). Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet., 26, 201-214.
3. BLONDEAU, N., LAURITZEN, I., WIDMANN, C., LAZDUNSKI, M. & HEURTEAUX, C. (2002). A potent protective role of lysophospholipids against global cerebral ischemia and glutamate excitotoxicity in neuronal cultures. J. Cereb. Blood Flow Metab., 22, 821-834.
4. BOCKENHAUER, D., ZILBERBERG, N. & GOLDSTEIN, S.A. (2001). KCNK2: reversible conversion of a hippocampal potassium leak into a voltage-dependent channel. Nat. Neurosci., 4, 486-491.
5. + channels. EMBO J., 22, 1-9.
6. CHOI, B.H., CHOI, J.S., YOON, S.H., RHIE, D.J., MIN, D.S., JO, Y.H., KIM, M.S. & HAHN, S.J. (2001). Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology, 41, 443-453.
7. CHOI, J.S., HAHN, S.J., RHIE, D.J., YOON, S.H., JO, Y.H. & KIM, M.S. (1999). Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3. J. Pharmacol. Exp. Ther., 291, 1-6.
8. + channel TREK-1 (hTREK-1) by fluoxetine. Br. J. Pharmacol., 138, 183P.
9. DEAK, F., LASZTOCZI, B., PACHER, P., PETHEO, G.L., KECSKEMETI, V. & SPAT, A. (2000). Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology, 39, 1029-1036.
10. DUNCAN, W.C., JOHNSON, K.A. & WEHR, T.A. (1995). Antidepressant drug-induced hypothalamic cooling in Syrian hamsters. Neuropsychopharmacology, 1, 17-37.
11. + channel. EMBO J., 15, 6854-6862.
12. GOLDSTEIN, S.A., BOCKENHAUER, D., O'KELLY, I. & ZILBERBERG, N. (2001). Potassium leak channels and the KCNK family of two-P-domain subunits. Nat. Rev. Neurosci., 2, 175-184.
13. + channels are a novel target for the anesthetic gases xenon, nitrous oxide and cyclopropane. Mol. Pharmacol., 65, 443-452.
14. + channels TREK-1 and TASK-3 are differentially modulated by copper and zinc. Mol. Pharmacol., 66, 530-537.
15. GU, W., SCHLICHTHORL, G., HIRSCH, J.R., ENGELS, H., KARSCHIN, C., KARSCHIN, A., DERST, C., STEINLEIN, O.K. & DAUT, J. (2002). Expression pattern and functional characteristics of two novel splice variants of the two-pore-domain potassium channel TREK-2. J. Physiol., 539, 657-668.
16. + channel. Cardiovasc. Res., 58, 46-54.
17. HERVIEU, G.J., CLUDERAY, J.E., GRAY, C.W., GREEN, P.J., RANSON, J.L., RANDALL, A.D. & MEADOWS, H.J. (2001). Distribution and expression of TREK-1, a two pore domain potassium channel in adult rat CNS. Neuroscience, 103, 899-919.
18. + channel involved in neuroprotection and general anaesthesia. EMBO J., 23, 2684-2695.
19. HIEMKE, C. & HARTTER, S. (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther., 85, 11-28.
20. HILLE, B. (2001). Ionic Channels of Excitable Membranes. Sunderland: Sinauer Associates Inc.
21. + channel TREK-1. EMBO J., 21, 2968-2976.
22. IFTINCA, M., WALDRON, G.J., TRIGGLE, C.R. & COLE, W.C. (2001). State-dependent block of rabbit vascular smooth muscle delayed rectifier and Kv1.5 channels by inhibitors of cytochrome P450-dependent enzymes. J. Pharmacol. Exp. Ther., 298, 718-728.
23. KARSON, C.N., NEWTON, J.E., LIVINGSTON, R., JOLLY, J.B., COOPER, T.B., SPRIGG, J. & KOMOROWSKI, R.A. (1993). Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci., 5, 322-329.
24. KENNARD, L.E., VEALE, E.L. & MATHIE, A. (2004). Inhibition of the human two-pore domain potassium channel, TREK1, by fluoxetine and its metabolite norfluoxetine. FENS Abstr., 2, A082.9.
25. KOH, S.D., MONAGHAN, K., SERGEANT, G.P., RO, S., WALKER, R.L., SANDERS, K.M. & HOROWITZ, B. (2003). TREK-1 regulation by nitric oxide and cGMP-dependent protein kinase. An essential role in smooth muscle inhibitory neurotransmission. J. Biol. Chem., 276, 44338-44346.
26. LAURITZEN, I., BLONDEAU, N., HEURTEAUX, C., WIDMANN, C., ROMEY, G. & LAZDUNSKI, M. (2000). Poly-unsaturated fatty acids are potent neuroprotectors. EMBO J., 19, 1784-1793.
27. LEE, S.-Y. & MACKINNON, R. (2004). A membrane-access mechanism of ion channel inhibition by voltage sensor toxins from spider venom. Nature, 430, 232-235.
28. LESAGE, F. (2003). Pharmacology of neuronal background potassium channels. Neuropharmacology, 44, 1-7.
29. + channel. EMBO J., 19, 2483-2491.
30. MAINGRET, F., PATEL, A.J., LESAGE, F., LAZDUNSKI, M. & HONORE, E. (1999). Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel. J. Biol. Chem., 274, 26691-26696.
31. + channels TREK-1 and TRAAK. J. Biol. Chem., 275, 10128-10133.
32. MATHIE, A., WOOLTORTON, J.R.A. & WATKINS, C.S. (1998). Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents. Gen. Pharmacol., 30, 13-24.
33. MEADOWS, H.J., BENHAM, C.D., CAIRNS, W., GLOGER, I., JENNINGS, C., MEDHURST, A.D., MURDOCK, P. & CHAPMAN, C.G. (2000). Cloning, localisation and functional expression of the human orthologue of the TREK-1 potassium channel. Pflugers Arch., 439, 714-722.
34. MEADOWS, H.J. & RANDALL, A.D. (2001). Functional characterization of human TASK-3, an acid-sensitive two-pore domain potassium channel. Neuropharmacology, 40, 551-559.
35. + channels - molecular sensors. Biochem. Biophys. Acta, 1566, 152-161.
36. ORSULAK, P.J., KENNEY, J.T., DEBUS, J.R., CROWLEY, G. & WITTMAN, P.D. (1988). Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection. Clin. Chem., 34, 1875-1878.
37. + channels by antidepressant drugs. J. Pharmacol. Exp. Ther., 284, 208-214.
38. + channels. Nat. Neurosci., 2, 422-426.
39. + channel. EMBO J., 17, 4283-4290.
40. SALZBERG, M. & VAJDA, F.J.E. (2001). Epilepsy, depression and antidepressant drugs. J. Clin. Neurosci., 8, 209-215.
41. STRAUSS, W.L., UNIS, A.S., COWAN, C., DAWSON, G. & DAGER, S.R. (2002). Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am. J. Psychiatry, 159, 755-760.
42. SUCHYNA, T.M., TAPE, S.E., KOEPPE, R.E., ANDERSEN, O.S., SACHS, F. & GOTTLIEB, P.A. (2004). Bilayer-dependent inhibition of mechanosensitive channels by neuroactive peptide enantiomers. Nature, 430, 235-240.
43. TALLEY, E.M., SOLORZANO, G., LEI, Q., KIM, D. & BAYLISS, D.A. (2001). CNS distribution of members of the two-pore-domain (KCNK) potassium channel family. J. Neurosci., 21, 7491-7505.
44. THOMAS, D., GUT, B., WENDT-NORDAHL, G. & KIEHN, J. (2002). The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J. Pharmacol. Exp. Ther., 300, 543-548.
45. WONG, D.T., BYMASTER, P.P. & ENGLEMAN, E.A. (1995). Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci., 57, 411-441.
46. v potassium currents by the antidepressant drug, fluoxetine. Br. J. Pharmacol., 128, 1609-1615.